Transcript Jan O. Johansson, MD, Ph.D. Senior Vice President

Resverlogix Corp.
TSX: RVX
October 7th, 2009
1
About Company
Resverlogix based in Calgary-based TSX-list biotech
company that is a world-leader in the development of
an oral therapy to actually regress plaque build-ups in
a person’s arteries.
Plaque build-up also known as atherosclerosis, is the
leading cause of cardiovascular disease (CVD), the
leading killer of men and women in the industrialized
world with over 18 million deaths reported in 2005
(World Health Organization).
2
About Company
NexVas™ Plaque Regression (NexVas PR), is a novel technology platform with
drugs that increase apolipoproteinA-I (ApoA-I) to reduce atherosclerosis (fatty
plaque build-up in the arteries), which is the leading cause of CVD. ApoA-I is
the key protective protein of high density lipoprotein (HDL), commonly known
as the “good cholesterol”. Current drugs on the market only manage
atherosclerosis burden but they have very limited or no effect on
atherosclerosis regression. NexVas PR aims to manage and regress
atherosclerosis. Resverlogix’s lead ApoA-I drug RVX-208 recently completed a
Phase 1b/2a human clinical trial.
3
Management
Donald J. McCaffrey
President and CEO, Co-Founder
Don is Resverlogix’s strategic leader, founder, mentor and the overall ‘heart’ of
the company.
Norman C.W. Wong, M.D., FRCP
Chief Scientific Officer & Co-Founder
Norman is the visionary for the scientific development of Resverlogix’s
therapeutic platforms.
Jan O. Johansson, M.D., Ph.D.
Senior Vice President Medical Affairs
Jan oversees the clinical and regulatory development, and provides scientific
guidance to the corporation.
4
Management
Kenneth Lebioda, BA
Senior VP Business & Corporate Development
Ken is responsible for the business and market development of the company’s
technology pipeline and alliance management.
Gregory S. Wagner, Ph.D., DABT
Senior VP Research & Development
Greg oversees the company’s preclinical programs and provides extensive
expertise in the areas of drug development, regulatory filings, and toxicology.
Dr. F. Allan Gordon, M.D., Ph.D
Senior Vice President of Clinical Development
Allan will lead Resverlogix through clinical development.
5
Share Structure & Financials
Shares Outstanding:
39.4M
Shares Fully Diluted:
49.6M
Options/Warrants:
10.2M
Current Price:
$2.81
52 Week High/Low:
$6.10/1.50
3 mo daily volume:
73,000
Cash on Hand:
$7M
6
1-Year Stock Chart
7
Calendar of Catalysts
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
X
Oct
Nov
Dec
X
X
Sept: Announced successful 1b/2a human clinical trial
Nov: Preparation of Stage 2 Human Clinical Trial by
IVUS (intravascular ultrasound)
Big Pharma could invest at any time
8
Why Invest Now?
 Recent US analyst coverage by Rodman & Renshaw
with 1-year $8 price target
 Moving towards a Stage 2 Human Clinical Trial
(IVUS)
 Big Pharma could invest at any time as financing
will need to be done prior to IVUS
 1-per-cent and 5-per-cent regression of
atherosclerosis would save the U.S. health care
system between $22.9-billion (U.S.) and $76.8billion (U.S.) annually
9
Contact
Contact:
Website:
Phone:
Email:
Graeme A. Dick
TSX: RVX
www.resverlogix.com
403-561-8989
[email protected]
10